Preparation and Characterization of High-Content Aripiprazole-Loaded Core-Shell Structure Microsphere for Long-Release Injectable Formulation

被引:11
作者
Hiraoka, Shogo [1 ,2 ]
Uchida, Shinya [1 ]
Namiki, Noriyuki [1 ]
机构
[1] Univ Shizuoka, Sch Pharmaceut Sci, Dept Pharm Practice & Sci, Suruga Ku, Shizuoka 4228526, Japan
[2] Otsuka Pharmaceut Co Ltd, Kawaguchi, Tokushima 7710182, Japan
关键词
core-shell structure microsphere; aripiprazole; depot formulation; poly(lactic acid); ANTIPSYCHOTIC ARIPIPRAZOLE; MEDICATION NONADHERENCE; PARTIAL AGONIST; SCHIZOPHRENIA; ADHERENCE; RECEPTORS; RELAPSE; 5-HT1A; RISK; DRUG;
D O I
10.1248/cpb.c14-00110
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The aim of this study was to obtain injectable high-drug-loading core-shell structure microspheres that release aripiprazole over 2 months. The microparticles were prepared by the oil-in-water emulsion solvent evaporation method and characterized. The microparticles were prepared with aripiprazole and 3 types of poly(lactic acid) (PLA) (DL-PLA: molecular weight (MW), ca. 20000; DL-PLA: MW, ca. 95000; or L-PLA: MW, ca. 110000), which were dissolved within the organic phase, and prepared in 3 temperature conditions for the external aqueous phase (two fixed temperature conditions and a gradually increased temperature condition). The theoretical drug loading in the particles was set to 80%. When prepared at fixed temperature conditions, all of the microparticles that were prepared with the 3 types of PLA were not spherical or smooth-surfaced. These microparticles released 100% of the drug within 1 week in the in vitro study. However, the microparticles that were prepared with DL-PLA (MW, 95000) in the gradually increased temperature condition were spherical with a smooth surface. The dissolution profile of the microparticles showed a long release over 7 weeks in vitro. The actual drug loading in the microspheres was 73-80%. A core-shell structure was observed in the inner structure of the microspheres. The core-shell microspheres were injected subcutaneously into rabbits. Aripiprazole was detected in the serum over 12 weeks. Production of high-drug-loading core-shell structure microspheres was successfully achieved by using high molecular weight of PLA and specific temperature condition at preparation. It showed long release profile in vitro and in vivo.
引用
收藏
页码:654 / 660
页数:7
相关论文
共 26 条
[1]  
[Anonymous], [No title captured]
[2]  
[Anonymous], [No title captured]
[3]  
[Anonymous], [No title captured]
[4]  
[Anonymous], [No title captured], Patent No. 4652441
[5]   Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors [J].
Burris, KD ;
Molski, TF ;
Xu, C ;
Ryan, E ;
Tottori, K ;
Kikuchi, T ;
Yocca, FD ;
Molinoff, PB .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) :381-389
[6]   Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia [J].
Byerly, Matthew J. ;
Thompson, Ann ;
Carmody, Thomas ;
Bugno, Rhiannon ;
Erwin, Thomas ;
Kashner, Michael ;
Rush, A. John .
PSYCHIATRIC SERVICES, 2007, 58 (06) :844-847
[7]  
David A S, 2001, Health Technol Assess, V5, P1
[8]   A Double-Blind, Randomized Comparative Study of Aripiprazole and Olanzapine in Patients with Schizophrenia [J].
Fleischhacker, W. Wolfgang ;
McQuade, Robert D. ;
Marcus, Ronald N. ;
Archibald, Donald ;
Swanink, Rene ;
Carson, William H. .
BIOLOGICAL PSYCHIATRY, 2009, 65 (06) :510-517
[9]   Polymer erosion in PLGA microparticles produced by phase separation method [J].
Husmann, M ;
Schenderlein, S ;
Lück, M ;
Lindner, H ;
Kleinebudde, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 242 (1-2) :277-280
[10]   The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor [J].
Jordan, S ;
Koprivica, V ;
Chen, RY ;
Tottori, K ;
Kikuchi, T ;
Altar, CA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 441 (03) :137-140